E
Citius Pharmaceuticals, Inc. CTXR
$0.85 $0.000.06% NASDAQ
Recommendation
Prev Close
$0.85
Volume
182,791
Avg Vol (90D)
932,263
Market Cap
$17.65M
Dividend & Yield
--
52-Week Range
$0.63 - $3.40
P/E (TTM)
--
EPS (TTM)
-$3.84
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Citius Pharmaceuticals (CTXR) Surges 22% After Hours Here's Why
12/24/2025 - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases
12/23/2025 - Nasdaq News: Markets
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss
12/23/2025 - GuruFocus
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
12/23/2025 - GuruFocus
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increased G&A Expenses
12/23/2025 - GuruFocus
Citius Pharmaceuticals GAAP EPS of -$3.38
12/23/2025 - Seeking Alpha - Healthcare
Citius Pharmaceuticals GAAP EPS of -$3.38
12/23/2025 - SeekingAlpha.com: All News
Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25
12/23/2025 - SeekingAlpha.com: All News
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
12/23/2025 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
12/23/2025 - PR Newswire
Citius Pharmaceuticals (NASDAQ:CTXR) vs. Tonix Pharmaceuticals (NASDAQ:TNXP) Critical Contrast
12/16/2025 - Ticker Report
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
12/10/2025 - PR Newswire
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
12/9/2025 - PR Newswire
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
12/4/2025 - PR Newswire
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma
12/1/2025 - TipRanks Financial Blog
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
12/1/2025 - PR Newswire
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Up 7% - Still a Buy?
11/26/2025 - Ticker Report
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
11/25/2025 - PR Newswire
Citius Oncology to advance launch of Lymphir with Verix AI integration
11/21/2025 - TipRanks Financial Blog
Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration
11/21/2025 - PR Newswire
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven?
10/28/2025 - Simply Wall St
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6. ...
10/21/2025 - GuruFocus
Citius Pharmaceuticals Secures $6M in Stock Offering
10/21/2025 - TipRanks Financial Blog
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
10/21/2025 - PR Newswire
Citius Pharmaceuticals Announces a Registered Direct Offering of $6. ...
10/21/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$38.52M
EBIT (TTM)
-$38.53M
Net Income (TTM)
-$37.43M
Balance Sheet
Total Assets (Q)
$130.94M
Total Debt (Q)
$1.81M
Total Liabilities (Q)
$53.41M
Book Value Per Share (Q)
$3.74
Cash Flow
Cash from Operations (TTM)
-$26.55M
Cash from Investing (TTM)
-$5.75M
Cash from Financing (TTM)
$33.30M
Net Change in Cash (TTM)
$1.00M
Filings
Filing Date
Tuesday, December 23, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 9 and 13 (est)
Price History
Loading...
Beta
2.06
7-Day Total Return
-1.48%
30-Day Total Return
-27.35%
60-Day Total Return
-45.16%
90-Day Total Return
-27.35%
Year to Date Total Return
0.24%
1-Year Total Return
-74.24%
2-Year Total Return
-94.69%
3-Year Total Return
-97.14%
5-Year Total Return
-97.21%
52-week Low
Dec 24, 2025 - $0.63
52-week High
Jan 24, 2025 - $3.40
Valuation
Market Cap
$17.65M - Nano Cap
Enterprise Value
$25.19M
Price/Sales (TTM)
--
Price/Book (Q)
0.23
Dividends and Shares
Shares Outstanding
17.20M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
citiuspharma.com
Phone Number
908 967 6677
Address
11 Commerce Drive
Cranford, NJ 07016
Country
United States
Year Founded
2007
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed